Healthcare provider profile · identity verified

Russell A Laforte, MD

Internal Medicine · GALVESTON, TX · NPI 1972662450

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	383	127
Amlodipine Besylate	Amlodipine Besylate	275	94
Lisinopril	Lisinopril	209	67
Losartan Potassium	Losartan Potassium	201	57
Hydrochlorothiazide	Hydrochlorothiazide	168	51
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	140	29
Metformin Hcl	Metformin Hcl	140	42
Mounjaro	Tirzepatide	139	21
Levothyroxine Sodium	Levothyroxine Sodium	127	47
Metoprolol Succinate	Metoprolol Succinate	120	41
Tamsulosin Hcl	Tamsulosin Hcl	116	42
Furosemide	Furosemide	105	38
Pantoprazole Sodium	Pantoprazole Sodium	103	36
Eliquis	Apixaban	90	24
Metformin Hcl Er	Metformin Hcl	82	24
Omeprazole	Omeprazole	81	30
Meloxicam	Meloxicam	79	20
Pravastatin Sodium	Pravastatin Sodium	76	25
Albuterol Sulfate Hfa	Albuterol Sulfate	75	22
Clopidogrel	Clopidogrel Bisulfate	74	18
Gabapentin	Gabapentin	74	27
Allopurinol	Allopurinol	70	20
Ozempic	Semaglutide	68	12
Clonazepam	Clonazepam	65	11
Acetaminophen-Codeine	Acetaminophen With Codeine	64	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	63	22
Trazodone Hcl	Trazodone Hcl	62	22
Rosuvastatin Calcium	Rosuvastatin Calcium	56	18
Tramadol Hcl	Tramadol Hcl	56	17
Zolpidem Tartrate	Zolpidem Tartrate	54	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	17
Fluoxetine Hcl	Fluoxetine Hcl	51	suppressed
Sertraline Hcl	Sertraline Hcl	49	12
Prednisone	Prednisone	47	29
Spironolactone	Spironolactone	47	14
Fluticasone Propionate	Fluticasone Propionate	45	18
Alendronate Sodium	Alendronate Sodium	43	15
Carvedilol	Carvedilol	42	17
Celecoxib	Celecoxib	42	13
Finasteride	Finasteride	40	14
Amitriptyline Hcl	Amitriptyline Hcl	38	16
Combivent Respimat	Ipratropium/Albuterol Sulfate	38	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	12
Pregabalin	Pregabalin	37	17
Trulicity	Dulaglutide	37	suppressed
Famotidine	Famotidine	36	14
Synthroid	Levothyroxine Sodium	34	11
Potassium Chloride	Potassium Chloride	32	11
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Atenolol	Atenolol	31	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	suppressed
Lorazepam	Lorazepam	31	suppressed
Simvastatin	Simvastatin	31	11
Bupropion Xl	Bupropion Hcl	29	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	27	suppressed
Enalapril Maleate	Enalapril Maleate	27	suppressed
Meclizine Hcl	Meclizine Hcl	27	suppressed
Alprazolam	Alprazolam	26	suppressed
Glipizide Er	Glipizide	26	suppressed
Xarelto	Rivaroxaban	26	suppressed
Guanfacine Hcl	Guanfacine Hcl	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Nifedipine Er	Nifedipine	23	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Donepezil Hcl	Donepezil Hcl	20	suppressed
Methocarbamol	Methocarbamol	20	11
Testosterone Cypionate	Testosterone Cypionate	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Azithromycin	Azithromycin	19	16
Digoxin	Digoxin	19	suppressed
Eplerenone	Eplerenone	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Jardiance	Empagliflozin	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Montelukast Sodium	Montelukast Sodium	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	15	suppressed
Lyumjev Kwikpen U-100	Insulin Lispro-Aabc	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Clonidine	Clonidine	14	suppressed
Eszopiclone	Eszopiclone	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Mometasone Furoate	Mometasone Furoate	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Bumetanide	Bumetanide	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Liothyronine Sodium	Liothyronine Sodium	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Risperidone	Risperidone	12	suppressed
Trospium Chloride Er	Trospium Chloride	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Fosinopril Sodium	Fosinopril Sodium	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Otezla	Apremilast	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Temazepam	Temazepam	11	suppressed
Testosterone	Testosterone	11	suppressed
Testosterone Enanthate	Testosterone Enanthate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error